Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (August 13th Preview)
-
Lung cancer – Phase 3 readout for exon 20 EGFR inhibitor sets up major FDA race
Taiho Oncology and Cullinan Therapeutics said zipalertinib has cleared a registrational Phase 3 endpoint in frontline EGFR exon 20 insertion lung cancer, using an early data check to halt enrollment once results were clearly positive. The oral EGFR inhibitor was tested in combination with chemotherapy versus chemotherapy plus placebo, with the companies saying the regimen met a pre-planned threshold for unblinding. The FDA is already reviewing zipalertinib for a second-line setting, with a decision expected by Feb. 27, and Taiho and Cullinan positioned the Phase 3 readout as a path to challenge the established exon 20 market that includes J&J’s Rybrevant and AstraZeneca’s Dizal’s Zegfrovy. The competitive stakes are high because exon 20 insertions represent a small but commercially attractive subset of EGFR-mutant disease. While detailed efficacy numbers were not provided in the report, the companies said the combination achieved a statistically significant and clinically meaningful progression-free survival improvement. Investigators previously tested zipalertinib in a Phase 2 setting showing tumor shrinkage or elimination in more than one-third of patients, supporting the continued registrational push. With ArriVent BioPharma also expecting Phase 3 data later this year, the zipalertinib update intensifies the timeline pressure on FDA review and increases the likelihood of rapid label expansion across line-of-therapy strategies in EGFR exon 20-positive NSCLC.
-
Neurodegeneration – CAR-T regimens move toward α-synuclein targeting in Parkinson’s
A preclinical study reported a first CAR-Treg concept aimed at a pathogenic form of α-synuclein in Parkinson’s disease. In two mouse models, engineered regulatory T cells recognizing α-synuclein reduced T cell–mediated inflammation, limited neurodegeneration, and improved motor performance. The approach uses CAR recognition to steer immunosuppression toward disease-linked α-synuclein species, with the investigators framing inflammation control as the lever behind neuroprotection. For Parkinson’s, the work aligns with a growing focus on immunomodulation rather than purely neuron-centric interventions. Because the data are in animals and involve engineered cells, clinical translation remains uncertain; however, the study provides a concrete target hypothesis—pathogenic α-synuclein—and a method for localized immune regulation. The next key step will be whether the strategy can achieve sustained benefit without broad immune suppression in more relevant models, including questions around safety, persistence, and the specificity of α-synuclein recognition.
-
Genie therapy – Sangamo Fabry assets auction accelerates PTC and Lilly entry
PTC Therapeutics and Eli Lilly are preparing to buy pieces of Sangamo Therapeutics’ Fabry disease gene therapy business via a bankruptcy auction, with Deal terms reported as up to $264 million for the combined transactions. The move reflects Wall Street’s view of Fabry gene therapy as a high-reward bet as a regulatory decision approaches. The auction outcome tees up a fast transition of development ownership for a field where timing is critical—especially with competitive enzyme replacement therapies still in the market and with investors watching how regulators weigh durability and safety. Analysts have characterized the transaction as riskier than traditional asset purchases due to execution and regulatory uncertainty, but the commercial upside is tied to the possibility of a near-term approval for an autologous gene therapy program. For PTC and Lilly, the purchase also positions them to influence the late-stage development plan and potential commercialization strategy should Fabry approval advance.
-
Oncology – Intranasal NEO100 shows Phase 2a endpoint hit in IDH1-mutant glioma
NeOnc Technologies reported Phase 2a results for intranasal NEO100 in recurrent IDH1-mutant high-grade glioma, saying the study met its primary endpoint for six-month progression-free survival. The company cited a PFS-6 of 48.9% against a pre-specified 20% benchmark, with a reported p-value of 0.0047. NeOnc also reported median overall survival of 26.09 months and survival rates of 86.7% at six months, 60.9% at 12 months, and 54.1% at 24 months. The trial enrolled 24 patients in an open-label design, and the update highlighted ongoing treatment in five patients, including one progression-free for about 19 months. Management said it plans to request a Type B meeting with the FDA to discuss a potential registrational development path. The company framed the results as early signal rather than proof, given the small cohort size and the lack of randomization. If regulators and future trials confirm benefit, intranasal delivery could differentiate NEO100 from more invasive approaches, but the key test will be whether the PFS-6 signal holds in larger controlled studies.
-
Rare disease antibodies – AbCellera raises $200M to fund ABCL635 and ABCL365 programs
AbCellera Biologics launched an underwritten public offering aimed at raising $200 million through a mix of common shares and pre-funded warrants. The financing is designed to fund continued clinical development of its menopause antibody ABCL365 and, centrally, its lead program ABCL635. The company said net proceeds will support ABCL635’s progression through clinical trials as well as working capital and general corporate purposes. Jefferies, J.P. Morgan, Cantor, UBS Investment Bank, and BMO Capital Markets are listed as joint book-running managers. AbCellera emphasized that completion of the offering is subject to market and other conditions, leaving timing and final structure dependent on investor appetite. Still, the deal highlights how clinical-stage biotechs with late-stage or pivotal-adjacent priorities are leaning on capital markets to extend runway and maintain trial pace. For ABCL635, the offering is a direct signal that AbCellera intends to keep resources aligned to its clinical milestone cadence, while ABCL365 continues progress in non-hormonal control of moderate-to-severe vasomotor symptoms via NK3R targeting.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.